Skip to main content

A Novel BERberine derivative for Malignant MESothelioma


Malignant Mesothelioma (MM) is a rare, aggressive and highly treatment-resistant malignancy arising in the thin layer of tissue known as mesothelium, which covers many of the important internal organs like the lungs, the peritoneal cavity, the heart and the testis.
The World Health Organization has recognized that all forms of mesothelioma are strongly associated with asbestos exposure and that its burden is increasing worldwide. Asbestos was definitely banned in European Union in January 2005. However, since the disease has a long latency period (44.6 years from exposure to diagnosis), peak incidences are expected in EU beyond 2020.
The standard first line treatment is the combination of pemetrexed and cisplatin with limited efficacy and side-effects. Despite a great deal of research has been undertaken during the last 10 years, none of the current drugs under clinical trials has shown yet an improvement in overall survival over existing standard therapy or solved the emergence of chemoresistance.
NAX035, an innovative berberine derivative has exhibited efficacy as antitumour agent with a good preliminary pharmacokinetic, toxicity and safety data when administered as oral therapy for the treatment of malignant mesothelioma. Activities of BERMES (BERberine derivative for MESothelioma treatment are expected to close the translational gap (death valley) by pulling the product up to the clinical development: BERMES will focus on completion of the non-clinical package and the drug manufacture with the aim of obtaining the orphan drug designation as well as to accomplish all the regulatory requirements required by the European Medicine Agency to achieve the clinical trial authorization to proceed into clinical trial right after the end of the project.

Call for proposal


See other projects for this call

Sub call



Net EU contribution
€ 1 085 659,75
C Baldiri Reixac 15
08028 Barcelona

See on map

Este Cataluña Barcelona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 465 282,75